Pascal Michael (BSc neuroscience and MSc clinical psychology) completed his PhD in psychology at the University of Greenwich on a comparative analysis of the neurophenomenology of both DMT (and analogous) experiences and the near-death experience. He is currently a lecturer there, teaching and researching psychedelics, NDEs, entity encounters, related exceptional human experiences, and the intersections therein.
Michael has presented at Breaking Conventions and for the Tyringham Initiative, and published in journals such as Frontiers. He is co-leader of the prof. cert. in Psychedelics, ASCs and Transpersonal Psychology, & supervisor and journal editor for the MSc in Transpersonal Psychology at the ALEF Trust. In 2020 he was the recipient of the Schmeidler Outstanding Student Award.


Lisa Luan has a background in clinical psychology and neuroscience and completed a research master’s degree in psychology at the University of Amsterdam. Currently a PhD student at the Centre for Psychedelic Research at Imperial College London, she leads a study developing continuous IV infusion as a novel method for DMT administration, and investigating the subjective, physiological and EEG effects of extended DMT infusions in healthy volunteers


Soma Makai-Bölöni research at the Centre for Human Drug Research revolves around setting-up and conducting clinical trials with psychedelic compounds, as well as developing novel methods for psychiatric and emotion focused research. He holds a research master’s in cognitive and clinical neuroscience with a specialisation in drug development and neurohealth from the University of Maastricht, and is currently a PhD candidate at Leiden University Medical Centre.


Carol Routledge is a dynamic R&D professional and drug development expert with over 30 years of experience within UK and US based pharmaceutical and biotechnology companies and the non-profit sector with a focus on drug acquisition and profiling of NCEs and biologics. Her clinical experience spans both psychiatric and neurological indications, with a strong focus on understanding and treating mental health disorders. 
Routledge also has experience managing a semi-philanthropic dementia fund with a key focus on identifying and developing novel disease-modifying mechanisms for the treatment of diseases that cause dementia, sourcing opportunities from academic research groups and small companies.


Parker Singleton (discussion moderator) has a diverse academic and professional background spanning organic chemistry, neuroscience, computational modeling, and teaching. Currently, he is a postdoctoral researcher in the Computational Connectomics Lab, where he studies and models the impacts of various forms of neuromodulation on brain dynamics to better understand brain function in altered states of consciousness (e.g. psychedelics), and derive targeted brain therapies for substance use disorder, depression, PTSD, and more.

Singleton also helps run the Machine Learning in Medicine (MLiM) virtual seminar series where speakers from around the world discuss topics related to the application of machine learning and computational tools towards better understanding and treating disease.